Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
The Roles of microRNAs in Cancer Aggressiveness and Drug Resistance,...
share announcement

The Roles of microRNAs in Cancer Aggressiveness and Drug Resistance, Volume II

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 6377

Special Issue Editors

Dr. Bi-Dar Wang

E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland Eastern Shore, One College Backbone Rd, Princess Anne, MD 21853, USA
Interests: cancer genomics; microRNA-mRNA interaction; aberrant RNA splicing; precision cancer biomarkers; molecular mechanisms underlying cancer drug resistance
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Luciane R Cavalli

E-Mail Website
Guest Editor
1. Professor, Research Institute Pelé Pequeno Príncipe, Faculdades Pequeno Príncipe, Curitiba, PR, Brazil
2. Adjunct Professor of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
Interests: cancer genomics; microRNA-mRNA interaction; aberrant RNA splicing; precision cancer biomarkers; molecular mechanisms underlying cancer drug resistance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This collection is the second edition of the Special Issue “The Roles of microRNAs in Cancer Aggressiveness and Drug Resistance” (https://www.mdpi.com/journal/cancers/special_issues/Aggressiveness_Resistance).

Mature microRNAs are small noncoding regulatory RNAs of 21-25 nucleotides in length that complementarily target mRNAs to promote mRNA degradation and/or inhibit protein translation. Emerging data suggest that microRNA aberration may play critical roles in cancer development and progression. Particularly, genomic studies (both array- and sequencing-based) have accelerated the identification of microRNA involvement in tumor pathogenesis. With scientific discoveries of oncogenic and tumor suppressive microRNAs and their roles in different cancer types, there is a great potential of developing microRNAs as precision biomarkers in cancer diagnosis and/or prognosis. Furthermore, several microRNAs tested in the preclinical models and clinical trials have shown promising therapeutic potentials, although finding an effective microRNA delivery system remains a challenge in microRNA-based therapeutics.

This Special Issue focuses on understanding the functional roles and molecular mechanisms of microRNAs in promoting cancer aggressiveness (i.e., metastasis) and treatment resistance. Novel strategies for developing microRNA-based biomarkers and therapeutics will be included, based on the functional/pathological implications of microRNAs in cancers.

Dr. Bi-Dar Wang
Prof. Dr. Luciane R Cavalli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microRNA
  • metastasis
  • treatment resistance
  • biomarker
  • drug target

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

27 pages, 3428 KiB  
Review
MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential
by Junjiang Fu, Saber Imani, Mei-Yi Wu and Ray-Chang Wu
Cancers 2023, 15(19), 4723; https://doi.org/10.3390/cancers15194723 - 26 Sep 2023
Cited by 2 | Viewed by 1590
Abstract
MicroRNA (miRNA) are small noncoding RNAs that play vital roles in post-transcriptional gene regulation by inhibiting mRNA translation or promoting mRNA degradation. The dysregulation of miRNA has been implicated in numerous human diseases, including cancers. miR-34 family members (miR-34s), including miR-34a, miR-34b, and [...] Read more.
MicroRNA (miRNA) are small noncoding RNAs that play vital roles in post-transcriptional gene regulation by inhibiting mRNA translation or promoting mRNA degradation. The dysregulation of miRNA has been implicated in numerous human diseases, including cancers. miR-34 family members (miR-34s), including miR-34a, miR-34b, and miR-34c, have emerged as the most extensively studied tumor-suppressive miRNAs. In this comprehensive review, we aim to provide an overview of the major signaling pathways and gene networks regulated by miR-34s in various cancers and highlight the critical tumor suppressor role of miR-34s. Furthermore, we will discuss the potential of using miR-34 mimics as a novel therapeutic approach against cancer, while also addressing the challenges associated with their development and delivery. It is anticipated that gaining a deeper understanding of the functions and mechanisms of miR-34s in cancer will greatly contribute to the development of effective miR-34-based cancer therapeutics. Full article
(This article belongs to the Special Issue The Roles of microRNAs in Cancer Aggressiveness and Drug Resistance, Volume II)
►▼ Show Figures

Figure 1

30 pages, 923 KiB  
Review
Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms
by Himali Gujrati, Siyoung Ha and Bi-Dar Wang
Cancers 2023, 15(12), 3140; https://doi.org/10.3390/cancers15123140 - 10 Jun 2023
Cited by 5 | Viewed by 2073
Abstract
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer deaths among American men. Complex genetic and epigenetic mechanisms are involved in the development and progression of PCa. MicroRNAs (miRNAs) are short noncoding RNAs that regulate protein [...] Read more.
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer deaths among American men. Complex genetic and epigenetic mechanisms are involved in the development and progression of PCa. MicroRNAs (miRNAs) are short noncoding RNAs that regulate protein expression at the post-transcriptional level by targeting mRNAs for degradation or inhibiting protein translation. In the past two decades, the field of miRNA research has rapidly expanded, and emerging evidence has revealed miRNA dysfunction to be an important epigenetic mechanism underlying a wide range of diseases, including cancers. This review article focuses on understanding the functional roles and molecular mechanisms of deregulated miRNAs in PCa aggressiveness and drug resistance based on the existing literature. Specifically, the miRNAs differentially expressed (upregulated or downregulated) in PCa vs. normal tissues, advanced vs. low-grade PCa, and treatment-responsive vs. non-responsive PCa are discussed. In particular, the oncogenic and tumor-suppressive miRNAs involved in the regulation of (1) the synthesis of the androgen receptor (AR) and its AR-V7 splice variant, (2) PTEN expression and PTEN-mediated signaling, (3) RNA splicing mechanisms, (4) chemo- and hormone-therapy resistance, and (5) racial disparities in PCa are discussed and summarized. We further provide an overview of the current advances and challenges of miRNA-based biomarkers and therapeutics in clinical practice for PCa diagnosis/prognosis and treatment. Full article
(This article belongs to the Special Issue The Roles of microRNAs in Cancer Aggressiveness and Drug Resistance, Volume II)
►▼ Show Figures

Figure 1

20 pages, 843 KiB  
Review
MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going
by Roberto Cuttano, Miriam Kuku Afanga and Fabrizio Bianchi
Cancers 2022, 14(23), 5731; https://doi.org/10.3390/cancers14235731 - 22 Nov 2022
Cited by 1 | Viewed by 2131
Abstract
Lung cancer is the leading cause of cancer-related mortality in the world. The development of drug resistance represents a major challenge for the clinical management of patients. In the last years, microRNAs have emerged as critical modulators of anticancer therapy response. Here, we [...] Read more.
Lung cancer is the leading cause of cancer-related mortality in the world. The development of drug resistance represents a major challenge for the clinical management of patients. In the last years, microRNAs have emerged as critical modulators of anticancer therapy response. Here, we make a critical appraisal of the literature available on the role of miRNAs in the regulation of drug resistance in non-small cell lung cancer (NSCLC). We performed a comprehensive annotation of miRNAs expression profiles in chemoresistant versus sensitive NSCLC, of the drug resistance mechanisms tuned up by miRNAs, and of the relative experimental evidence in support of these. Furthermore, we described the pros and cons of experimental approaches used to investigate miRNAs in the context of therapeutic resistance, to highlight potential limitations which should be overcome to translate experimental evidence into practice ultimately improving NSCLC therapy. Full article
(This article belongs to the Special Issue The Roles of microRNAs in Cancer Aggressiveness and Drug Resistance, Volume II)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop